
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    ### **Step-by-Step Analysis of the Provided Marker List**<br><br>#### **1. List the Key Functional Markers and Their Roles**  <br>The provided markers are overwhelmingly associated with **cell cycle progression, mitosis, and chromosome segregation**. Below is a breakdown of key functional groups:<br><br>- **Mitotic Regulation & Chromosome Segregation:**  <br>  - *HJURP, CENPA, PBK, AURKB, DLGAP5, KIF2C, KIF15, BIRC5, SPC25, ASPM, KIF18B, CEP55, NUF2, SKA3, SPC24, TTK, PLK1, NEK2*  <br>  - These genes regulate spindle assembly, kinetochore-microtubule attachment, and chromosome condensation.<br><br>- **DNA Replication & Cell Cycle Progression:**  <br>  - *CDC45, CDCA5, TOP2A, PCLAF, MND1, RRM2, CCNB2, DTL, PKMYT1, CDCA3, CDK1, TK1, CDC25C, CDT1, CCNA2*  <br>  - These genes are critical for S-phase (DNA replication) and G2/M transition (cyclins, CDKs, and checkpoint regulators).<br><br>- **Proliferation Markers:**  <br>  - *MKI67, FOXM1*  <br>  - These are universal markers of actively cycling cells.<br><br>- **DNA Damage Response & Repair:**  <br>  - *POLQ, RAD51AP1*  <br>  - Involved in DNA repair mechanisms, often upregulated in rapidly dividing cells.<br><br>#### **2. List the Key Cell Type Markers**  <br>The list **lacks canonical markers for differentiated cell types** (e.g., epithelial, immune, stromal, or neuronal markers). Instead, it is dominated by **cell cycle-associated genes**, strongly suggesting a **proliferating cell population**.<br><br>#### **3. Cross-reference Known Databases**  <br>- **Cell Cycle Signatures (CellMarker, PanglaoDB, Human Cell Atlas):**  <br>  - The markers align with **cycling epithelial cells** (e.g., intestinal crypt stem/progenitor cells) or **transient amplifying (TA) cells** in the gut.  <br>  - *HJURP, UBE2C, CENPA, TOP2A, MKI67, FOXM1* are highly expressed in **intestinal stem cells (LGR5+)** and **progenitor cells**.  <br>  - *AURKB, PLK1, CDK1* are enriched in **mitotic cells** (e.g., crypt base columnar cells).  <br><br>- **Cancer vs. Normal Proliferating Cells:**  <br>  - While some markers (e.g., *BIRC5, ASPM*) are also seen in cancer, the absence of oncogenic drivers (e.g., *MYC, KRAS*) suggests **normal cycling cells** rather than tumor cells.  <br><br>#### **4. Determine the Most Probable General Cell Type**  <br>Given the **intestinal tissue origin** and the **proliferation signature**, the most likely general cell type is:  <br>**Proliferating Epithelial Cells (likely intestinal crypt stem/progenitor cells).**<br><br>#### **5. Identify the Top 3 Most Probable Sub Cell Types**  <br>Ranked by likelihood:  <br><br>1. **Transient Amplifying (TA) Cells**  <br>   - High expression of *MKI67, TOP2A, CDK1, CCNB2* matches TA cells in intestinal crypts.  <br>   - *FOXM1* is a key regulator of TA proliferation.  <br><br>2. **Intestinal Stem Cells (LGR5+)**  <br>   - *HJURP, UBE2C, CENPA* are seen in stem cells but usually at lower levels than TA cells.  <br>   - Stem cells typically co-express *OLFM4, LGR5*, which are absent here.  <br><br>3. **Enterocyte Progenitors (Early Differentiating)**  <br>   - Some markers (*CDCA5, CDC45*) are seen in early differentiation, but the strong mitotic signature favors TA cells.  <br><br>**Most Likely Subtype:** **Transient Amplifying (TA) Cells**  <br><br>#### **6. Concise Summary of Analysis**  <br>- The marker list is **dominated by cell cycle and mitosis genes**, ruling out quiescent or terminally differentiated cells.  <br>- The **absence of immune/stromal markers** and the **intestinal tissue origin** strongly suggest **proliferating epithelial cells**.  <br>- The **high mitotic activity** and **lack of stem cell-specific markers** point to **TA cells** as the most probable identity.  <br><br>**FINAL ANNOTATION COMPLETED:**  <br>**Cell Type:** **Proliferating Epithelial Cells (Transient Amplifying Cells) of the Intestinal Crypt**  <br><br>*(If additional markers like LGR5, OLFM4, or KRT20 were present, the annotation could be refined further.)*
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED  <br><br>### **Feedback & Justification:**  <br><br>1. **Marker Consistency:**  <br>   - The provided **marker list is strongly enriched for cell cycle, mitosis, and proliferation-associated genes** (*MKI67, TOP2A, CDK1, CCNB2, FOXM1, AURKB, PLK1*), which aligns perfectly with the annotation of **proliferating epithelial cells (Transient Amplifying Cells)**.  <br>   - No contradictory markers (e.g., immune, stromal, or terminally differentiated epithelial markers) are present.  <br><br>2. **Tissue Context & Biological Plausibility:**  <br>   - Given the **intestinal origin**, the annotation as **intestinal crypt TA cells** is well-supported, as these cells are known for high proliferation.  <br>   - The absence of **LGR5/OLFM4** (stem cell markers) and **KRT20** (mature enterocyte marker) further refines the annotation to **TA cells** rather than stem or differentiated cells.  <br><br>3. **Mixed Population Consideration:**  <br>   - No evidence of mixed cell types, as all top markers consistently point to a **cycling epithelial population**.  <br><br>4. **Database Cross-Validation:**  <br>   - The markers (*HJURP, CENPA, TOP2A, MKI67*) match known **intestinal TA cell signatures** (CellMarker, PanglaoDB).  <br>   - The lack of oncogenic markers (*MYC, KRAS*) supports a **normal proliferating population** rather than cancer.  <br><br>### **Minor Suggestion (Optional Refinement):**  <br>If additional data (e.g., *LGR5, OLFM4, KRT20*) becomes available, the annotation could be further stratified into:  <br>   - **LGR5+ stem cells** (if stem markers appear),  <br>   - **Early enterocyte progenitors** (if differentiation markers emerge).  <br><br>**Conclusion:** The annotation is **biologically sound and well-supported by the markers**. No revision is needed unless new data contradicts this conclusion.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Proliferating Epithelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Transient Amplifying (TA) Cells</li><li>Intestinal Stem Cells (LGR5+)</li><li>Enterocyte Progenitors (Early Differentiating)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">95</div>
                        <div class="scoring-content">
                            The annotation results demonstrate a strong and scientifically accurate analysis of the provided marker list, with several notable strengths:<br><br>1. **Correctness of Annotations**:  <br>   - The annotation correctly identifies the dominant cell cycle and proliferation signature, ruling out non-proliferating or differentiated cell types. The conclusion that these are **proliferating epithelial cells (Transient Amplifying Cells)** is well-supported by the markers (e.g., *MKI67, TOP2A, CDK1, FOXM1*).  <br>   - The exclusion of immune/stromal markers and the focus on intestinal crypt biology (e.g., TA cells) are biologically plausible and align with known intestinal epithelial hierarchies.  <br><br>2. **Balanced Consideration of Markers**:  <br>   - The analysis does not overemphasize a single marker but instead groups genes into functional categories (mitosis, DNA replication, proliferation), providing a holistic view. For example, *HJURP, CENPA, AURKB* are discussed alongside *MKI67, FOXM1*, ensuring no single gene dominates the interpretation.  <br>   - The absence of *LGR5/OLFM4* (stem cell markers) and *KRT20* (mature enterocyte marker) is explicitly noted, reinforcing the TA cell annotation.  <br><br>3. **Comprehensive View of Cell Populations**:  <br>   - The annotation captures the general picture well: a homogeneous proliferating epithelial population without evidence of mixed cell types. The top sub-cell types (TA cells, stem cells, enterocyte progenitors) are ranked logically, with TA cells being the most probable.  <br>   - The optional refinement (if *LGR5* or *KRT20* were present) shows foresight but does not detract from the current confidence in the annotation.  <br><br>4. **Database Cross-Validation**:  <br>   - References to CellMarker, PanglaoDB, and the Human Cell Atlas lend credibility to the annotation. The distinction between normal proliferating cells and cancer (e.g., lack of *MYC/KRAS*) is a thoughtful touch.  <br><br>**Minor Weaknesses**:  <br>- While the analysis is thorough, it could briefly acknowledge potential limitations (e.g., whether the markers are derived from scRNA-seq or bulk data, as bulk data might obscure rare cell types).  <br>- The rank of markers (e.g., *HJURP* appearing first) is not explicitly discussed, though the functional grouping mitigates this.  <br><br>**Overall**, the annotation is robust, well-reasoned, and captures the essence of the data. The minor weaknesses do not significantly detract from its quality.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    